Barahona-Garrido Josue, Camacho-Escobedo Jesus, Cerda-Contreras Eduardo, Hernandez-Calleros Jorge, Yamamoto-Furusho Jesus K, Torre Aldo, Uribe Misael
Department of Gastroenterology, National Institute of Health Sciences and Nutrition Salvador Zubiran, Mexico City 14000, Mexico.
World J Gastroenterol. 2008 May 28;14(20):3195-200. doi: 10.3748/wjg.14.3195.
To evaluate the factors that influence outcome of both non-invasive and invasive treatment of polycystic liver disease.
Analysis of clinical files of patients with complete follow-up from July 1986 to June 2006.
Forty-one patients (male, 7; female, 34), 47.8 +/- 11.9 years age, and 5.7 +/- 6.7 years follow-up, were studied. Alkaline phosphatase (AP) elevation (15% of patients) was associated with the requirement of invasive treatment (IT, P = 0.005). IT rate was higher in symptomatic than non-symptomatic patients (65.4% vs 14.3%, P = 0.002), and in women taking hormonal replacement therapy (HRT) (P = 0.001). Cysts complications (CC) were more frequent (22%) in the symptomatic patients group (P = 0.023). Patients with body mass index (BMI) > 25 (59%) had a trend to complications after IT (P = 0.075). Abdominal pain was the most common symptom (56%) and indication for IT (78%). Nineteen patients (46%) required a first IT: 12 open fenestration (OF), 4 laparoscopic fenestration (LF) and 3 fenestration with hepatic resection (FHR). Three required a second IT, and one required a third procedure. Complications due to first IT were found in 32% (OF 16.7%, LF 25%, FHR 66.7%), and in the second IT in 66.7% (OF 100%). Follow-up mortality rate was 0.
Presence of symptoms, elevated AP, and CC are associated with IT requirement. HRT is associated with presence of symptoms and IT requirement. Patients with BMI > 25 have a trend be susceptible to IT complications. The proportions of complications are higher in FHR and second IT groups. RS is more frequent after OF.
评估影响多囊肝病非侵入性和侵入性治疗结果的因素。
分析1986年7月至2006年6月有完整随访资料的患者临床档案。
研究了41例患者(男性7例,女性34例),年龄47.8±11.9岁,随访5.7±6.7年。碱性磷酸酶(AP)升高(15%的患者)与侵入性治疗(IT)需求相关(P = 0.005)。有症状患者的IT率高于无症状患者(65.4%对14.3%,P = 0.002),且在接受激素替代疗法(HRT)的女性中更高(P = 0.001)。症状性患者组的囊肿并发症(CC)更常见(22%)(P = 0.023)。体重指数(BMI)>25的患者(59%)在IT后有并发症倾向(P = 0.075)。腹痛是最常见的症状(56%)和IT指征(78%)。19例患者(46%)需要首次IT:12例开放性开窗术(OF),4例腹腔镜开窗术(LF),3例开窗术联合肝切除术(FHR)。3例需要第二次IT,1例需要第三次手术。首次IT的并发症发生率为32%(OF为16.7%,LF为25%,FHR为66.7%),第二次IT的并发症发生率为66.7%(OF为100%)。随访死亡率为0。
症状的出现、AP升高和CC与IT需求相关。HRT与症状的出现和IT需求相关。BMI>25的患者有易发生IT并发症的倾向。FHR组和第二次IT组的并发症比例更高。OF后残余囊肿更常见。